Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Naspi, Antimo ^a   Panasiti, Vincenzo ^b   Abbate, Franco ^a   Roberti, Vincenzo ^a   Devirgiliis, Valeria ^b   Curzio, Michela ^a   Borghi, Martina ^c   Lozupone, Francesco ^c   Carotti, Simone ^b   Morini, Sergio ^b   Gaudio, Eugenio ^a   Calvieri, Stefano ^a   Londei, Paola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORUS; PROTEOME; RINFABATE; SOMATOMEDIN BINDING PROTEIN 3; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEIN KINASE B; RECOMBINANT PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOCYTE; MELANOMA; MIDDLE AGED; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ZYMOGRAPHY; ANIMAL; BLOOD; CELL MOTION; DISEASE COURSE; DRUG EFFECTS; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; SURVIVAL; TUMOR CELL LINE; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION;

ADULT; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MELANOCYTES; MELANOMA; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84902595685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098641     Document Type: Article

References (27)

1. Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. Nov 15;18(22):3782-93
2. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK et al. (2000) The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer.;88:2398-2424 (Pubitemid 30247142)
3. Lomas J, Martin-Duque P, Pons M, Quintanilla M (2008) The genetics of malignant melanoma. Front Biosci; 13: 5071-5093 (Pubitemid 351599659)
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol.; 27(36):6199-206
5. Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev.;20(6):761-87 (Pubitemid 30648894)
6. Ali O, Cohen P, Lee KW (2003) Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 35: 726-733, (Pubitemid 38058176)
7. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353, (Pubitemid 38529873)
8. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L et al. (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-471, W483-468
9. Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV et al. (2006) Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 147: 3484-3500, (Pubitemid 43901140)
10. Zumkeller W (2001) IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? Mol. Pathol.; 54(5):285-288
11. LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137. (Pubitemid 36588961)
12. Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y et al. (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGFbinding protein-3. J Natl Cancer Inst;91:620-5. (Pubitemid 29194048)
13. Yu H, Spitz MR, Mistry J, Gu J, Hong WK et al. (1999) Plasma levels of insulin-like growth factor I and lung cancer risk: a case-control analysis. J Natl Cancer Inst;91:151-6. (Pubitemid 29042692)
14. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS et al (1998) Circulating concentrations of insulinlike growth factor I and risk of breast cancer. Lancet;351:1393-6. (Pubitemid 28209997)
15. Panasiti V, Naspi A, Devirgiliis V, Curzio M, Roberti V et al. (2011) Correlation between insulin-like growth factor binding protein-3 serum level and melanoma progression. J Am Acad Dermatol.;64(5):865-72.
16. E.A. . Eisenhauera, P. . Therasseb, J. . Bogaertsc, Schwartz LH, Sargent D et al. (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Can 45 228-247
17. Friedrich N, Alte D, Völzke H, Spilcke-Liss E, Lüdemann J et al. (2008) Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res.;18(3):228-37 (Pubitemid 351479927)
18. Lal G, Contreras PG, Kulak M, Woodfield G, Bair T et al. (2013) Melanoma cells over-express extracellular matrix 1 (ECM1) which is regulated byTFAP2C. PLoS One. Sep 2;8(9):e73953.
19. Baldini PM, Lentini A, Mattioli P, Provenzano B, De Vito P et al. (2006) Decrease of polyamine levels and enhancement of transglutaminase activity in selective reduction of B16-F10 melanoma cell proliferation induced by atrial natriuretic peptide. Melanoma Res. Dec;16(6):501-7
20. Lozupone F, Luciani F, Venditti M, Rivoltini L, Pupa S et al. (2000) Murine granulocytes control human tumor growth in SCID mice. Int J Cancer. Aug 15;87(4):569-73
21. Mattei F, Schiavoni G, De Ninno A, Lucarini V, Sestili P et al. (2014) Multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. J Immunotoxicol.
22. Geran RI, Greenberg NH, Macdonald MM, Shumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. 3rd ed. Cancer Chemother Rep:3:1-88
23. Schoonjans F, Zalata A, Depuydt CE, Comhaire FH (1995) MedCalc: a new computer 312 program for medical statistics. Comput Methods Programs Biomed.; 48(3):257-62 (Pubitemid 26020881)
24. Dar AA, Majid S, Nosrati M, de Semir D, Federman S et al. (2010) Functional modulation of IGF-binding protein-3 expression in melanoma. J Invest Dermatol.;130(8):2071-9
25. Bellei B, Flori E, Izzo E, Maresca V, Picardo M (2008) GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signal.;20(10):1750-61
26. Mehta HH, Gao Q, Galet C, Paharkova V, Wan J et al. (2011) IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res.;71(15):5154-63
27. Gribben L, Baxter RC, Marsh DJ (2012) Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells. Cancer Lett.;317(1):41-8